文献速递结核与非结核分枝杆菌

结核预防治疗中标准与高剂量利福平的人群药代动力学模型:2R2随机对照试验

Population Pharmacokinetic Modeling of Standard- and High-Dose Rifampicin for Tuberculosis Preventive Therapy in the 2R2 Randomized Controlled Trial.
PubMed 文献 · J Infect Dis · 2026-01-01

在2R2随机试验中,对1368例结核感染者的440例进行利福平人群药代动力学建模,比较2个月高剂量(20或30 mg/kg/日)与4个月标准剂量(10 mg/kg/日)方案。高剂量利福平因非线性清除导致暴露量增加超过剂量比例,且国家间(印尼、越南、加拿大)暴露存在显著差异,可能与制剂、去脂体重等因素有关。

要点

  • 高剂量利福平用于预防治疗时,暴露量增加超过剂量比例。
  • 国家间利福平暴露差异显著,加拿大和越南生物利用度低于印尼。
  • 去脂体重和制剂差异可能影响利福平药代动力学。

核心结论

  • 高剂量利福平预防治疗导致暴露量增加超过剂量比例,源于高剂量下非线性清除。
  • 国家间暴露差异显著,可能与制剂、去脂体重及未测量混杂因素有关。

研究设计与样本

  • 在2R2随机对照试验中嵌套进行密集和稀疏药代动力学亚研究,纳入440例结核感染者。
  • 2R2试验比较2个月高剂量利福平20 mg/kg/日(2R20)或30 mg/kg/日(2R30)与4个月标准剂量10 mg/kg/日(4R10),受试者为≥10岁青少年和成人。

主要发现

  • 440例模型开发对象中,191例(43%)接受4R10,159例(36%)接受2R20,90例(20%)接受2R30。
  • 加拿大生物利用度较印尼低21.8%(95%CI -27.9至-18.0%),越南低12.3%(95%CI -17.7至-7.9%)。
  • 24小时浓度-时间曲线下面积随剂量增加呈超比例增加,印尼各治疗组暴露均高于越南和加拿大。

临床怎么用

  • 高剂量利福平预防治疗需考虑剂量非线性及国家间暴露差异对疗效和安全性的潜在影响。

局限性

  • 国家间差异可能受未测量混杂因素影响,具体机制需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: High-dose rifampicin could potentially shorten tuberculosis preventive therapy (TPT) and improve outcomes. We aimed to characterize population pharmacokinetics of standard- and high-dose rifampicin for TPT among individuals with tuberculosis infection. METHODS: Intensive and sparse pharmacokinetic substudies were conducted in Indonesia, Canada, and Vietnam within the 2R2 randomized trial, which compared 2 months of high-dose rifampicin at 20 mg/kg/day (2R20) or 30 mg/kg/day (2R30) with 4 months of standard-dose rifampicin at 10 mg/kg/day (4R10) in adults and adolescents aged ≥ 10 years. Venous blood samples were collected after 4 weeks of treatment. Rifampicin pharmacokinetics were analyzed using nonlinear mixed-effects modeling in NONMEM. RESULTS: Among 1368 trial participants, 440 were included in model development (51 intensive and 389 sparse sampling), with 191 (43%) assigned to 4R10, 159 (36%) to 2R20, and 90 (20%) to 2R30. A 1-compartment model with saturable hepatic extraction and transit-compartment absorption best described rifampicin pharmacokinetics. All disposition parameters were allometrically scaled using fat-free mass. Country-specific differences, particularly variation in drug formulation, were associated with lower bioavailability in Canada {-21.8% (95% confidence interval [CI] -27.9 to -18.0%)} and Vietnam (-12.3% [95% CI -17.7 to -7.9%]) compared with Indonesia. The 24-hour area under the concentration-time curve increased more than proportionally with dose and was higher across treatment arms in Indonesia, followed by Vietnam and Canada. CONCLUSIONS: High-dose rifampicin for TPT resulted in greater-than-proportional increases in exposure due to nonlinear clearance at higher doses. Substantial between-country variability in exposure was observed, which may have been due to multiple factors, including differences in country-specific formulations, fat-free mass, and unmeasured confounders.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Gafar F, Svensson EM, Yunivita V, et al. Population Pharmacokinetic Modeling of Standard- and High-Dose Rifampicin for Tuberculosis Preventive Therapy in the 2R2 Randomized Controlled Trial. J Infect Dis. 2026. PMID: 41589392. doi:10.1093/infdis/jiag052

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。